

# Câncer Colo-retal

## **5-Fluorouracil + Radioterapia**

5-Fluorouracil: 1,000 mg/m<sup>2</sup>/dia IV infusão contínua D1 a 5

Repetir nas semanas 1 e 5 da radioterapia

5-Fluorouracil: 500 mg/m<sup>2</sup> IV contínuo durante 5 dias a cada 28 dias por 4 ciclos Ref. (1)

## **Capecitabina + Radioterapia**

Capecitabina: 825 mg/m<sup>2</sup> VO BID durante toda a radioterapia

**OU**

Capecitabina: 900–1,000 mg/m<sup>2</sup> VO BID D1–5 de cada semana da radioterapia Ref. (2)

## **5-Fluorouracil + Leucovorin (Mayo Clinic)**

5-Fluorouracil: 425 mg/m<sup>2</sup> IV D–5

Leucovorin: 20 mg/m<sup>2</sup> IV D1–5 (administrado antes do 5-Fluorouracil)

a cada 28 dias Ref. (3)

## **5-Fluorouracil + Leucovorin (Roswell Park)**

5-Fluorouracil: 500 mg/m<sup>2</sup> IV semanalmente por 6 semanas

Leucovorin: 500 mg/m<sup>2</sup> IV em 2 horas semanalmente por

6 semanas, administrado antes do 5-Fluorouracil

a cada 8 semanas Ref. (4)

## **5-Fluorouracil + Leucovorin**

5-Fluorouracil: 500 mg/m<sup>2</sup> IV semanalmente por 6 semanas

Leucovorin: 20 mg/m<sup>2</sup> IV semanalmente por 6 semanas,

Administrado antes do 5-Fluorouracil

a cada 8 semanas Ref. (5)

### **Quasar**

5-Fluorouracil: 370mg/m<sup>2</sup> IV

Leucovorin: 25 ou 175mg IV (dose fixa)

Uma vez por semana, por 30 semanas (29, 38)

### **FOLFOX4**

Oxaliplatina: 85 mg/m<sup>2</sup> IV D1

5-Fluorouracil: 400 mg/m<sup>2</sup> IV pulso, seguido por 600 mg/m<sup>2</sup> IV infusão contínua por 22 horas D1 e 2

Leucovorin: 200 mg/m<sup>2</sup> IV D1 e 2 em uma infusão de 2 horas, antes do 5-Fluorouracil.

a cada 2 semanas

Ref. (6)

### **FLOX Nórdico**

Oxaliplatina: 85mg/m<sup>2</sup> IV em 2 horas D1

5-Fluorouracil: 500mg/m<sup>2</sup> IV pulso D1 e D2

Leucovorin: 60mg/m<sup>2</sup> IV pulso D1 e D2

Intervalo a cada 14 dias

Ref. (30)

### **ROX**

Oxaliplatina: 85mg/m<sup>2</sup> IV 2 horas D1 e D15

Leucovorin: 250mg/m<sup>2</sup> IV 2horas D1, 8 e 15

5-Fluorouracil: 500mg/m<sup>2</sup> IV pulso, D1, 8 e 15 a cada 4 semanas (31)

### **Capecitabina**

Capecitabina: 1,250 mg/m<sup>2</sup> VO BID D1–14

a cada 21 dias

Ref. (7)

### **Irinotecano + 5-Fluorouracil + Leucovorin (IFL)**

Irinotecano: 125 mg/m<sup>2</sup> IV em 90 minutos semanalmente por 4 semanas

5-Fluorouracil: 500 mg/m<sup>2</sup> IV semanalmente por 4 semanas

Leucovorin: 20 mg/m<sup>2</sup> IV semanalmente por 4 semanas

a cada 6 semanas

Ref. (8)

### **Irinotecano + 5-Fluorouracil + Leucovorin (IFL) + Bevacizumabe (BV)**

Irinotecano: 125 mg/m<sup>2</sup> IV em 90 minutos semanalmente por 4 semanas (D1, 8, 15, 22)

5-Fluorouracil: 500 mg/m<sup>2</sup> IV semanalmente por 4 semanas (D1, 8, 15, 22)

Leucovorin: 20 mg/m<sup>2</sup> IV semanalmente por 4 semanas (D1, 8, 15, 22)

Bevacizumabe: 5 mg/kg IV a cada 2 semanas D1, 15 a cada 6 semanas

Ref. (9)

### **IFL (Regime de Douillard)**

Irinotecano: 180 mg/m<sup>2</sup> IV D1

5-Fluorouracil: 400 mg/m<sup>2</sup> IV pulso, seguido por 600 mg/m<sup>2</sup> IV infusão contínua por 22 horas D1 e 2

Leucovorin: 200 mg/m<sup>2</sup> IV D1 e 2 em 2 horas (infundir antes do 5-Fluorouracil)

a cada 2 semanas

Ref. (11)

### **FOLFIRI**

Irinotecano: 180 mg/m<sup>2</sup> IV D1

5-Fluorouracil: 400 mg/m<sup>2</sup> IV pulso D1, seguido por 2.400 mg/m<sup>2</sup> IV infusão contínua por 46 horas.

Leucovorin: 200 mg/m<sup>2</sup> IV D1 em 2 horas (infundir antes do 5-Fluorouracil)

a cada 2 semanas

Ref. (12)

### **FOLFOX6**

Oxaliplatina: 100 mg/m<sup>2</sup> IV D1

5-Fluorouracil: 400 mg/m<sup>2</sup> IV pulso D1, seguido por 2.400 mg/m<sup>2</sup> IV por infusão contínua em 46 horas.

Leucovorin: 400 mg/m<sup>2</sup> IV D1 em 2 horas (infundir antes do 5-Fluorouracil)

a cada 2 semanas

Ref. (13)

### **m FOLFOX6**

Oxaliplatina: 85 mg/m<sup>2</sup> IV em 2 horas D1

Leucovorin: 350 mg/m<sup>2</sup> IV em 2 horas D1

5-Fluorouracil: 400 mg/m<sup>2</sup> IV pulso D1, seguido por  
2.400 mg/m<sup>2</sup> IV em infusão contínua de 46 horas.

a cada 2 semanas por 12 ciclos

Ref. (39)

### **FOLFOX7**

Oxaliplatina: 130 mg/m<sup>2</sup> IV D1

5-Fluorouracil: 2.400 mg/m<sup>2</sup> IV infusão contínua D1 e 2 por 46  
horas.

Leucovorin: 400 mg/m<sup>2</sup> IV D1 em 2 horas (infundir antes do 5-  
Fluorouracil)

a cada 2 semanas

Ref. (13)

### **FOLFOXIRI**

Irinotecano: 150mg/m<sup>2</sup> IV D1

Oxaliplatina: 65mg/m<sup>2</sup> IV D2

Leucovorin: 200mg/m<sup>2</sup> IV D2 e D3

5-Fluorouracil: 400mg/m<sup>2</sup> IV pulso D2 e D3

5-Fluorouracil: 600mg/m<sup>2</sup> IV em infusão contínua D2 e D3

a cada 15 dias

Ref. (32)

### **Cetuximabe + Irinotecano**

Cetuximabe: 400 mg/m<sup>2</sup> IV dose de ataque, seguido de  
250 mg/m<sup>2</sup>

IV semanalmente

Irinotecano: 350 mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref. (14)

### **XELOX**

#### **Capecitabina + Oxaliplatina**

Capecitabina: 1,000 mg/m<sup>2</sup> VO BID D1–14

Oxaliplatina: 130 mg/m<sup>2</sup> IV D1

a cada 21 dias

Capecitabina: 1.750 mg/m<sup>2</sup> VO BID D1–7

Oxaliplatina: 85 mg/m<sup>2</sup> IV D1

a cada 14 dias

Ref. (15)

### **XELIRI**

Capecitabina: 1.000 mg/m<sup>2</sup> VO BID D1–14

Irinotecano: 250 mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref. (16)

### **IROX**

#### **Oxaliplatina + Irinotecano**

Oxaliplatina: 85 mg/m<sup>2</sup> IV D1

Irinotecano: 200 mg/m<sup>2</sup> IV D1

a cada 3 semanas

Ref. (17)

#### **Raltitrexede + Oxaliplatina**

Raltitrexede: 2,5mg/m<sup>2</sup> IV em 15 minutos D1

Oxaliplatina: 100mg/m<sup>2</sup> IV em 180 minutos D1

a cada 3 semanas

Ref. (33)

Raltitrexede: 3mg/m<sup>2</sup> IV D1

Mitomicina C: 6mg/m<sup>2</sup> IV D1

a cada 4 semanas

Ref. (34)

### **OU**

Raltitrexede: 3mg/m<sup>2</sup> IV D1 a cada 3 semanas

Mitomicina C: 7mg/m<sup>2</sup> IV D1 a cada 6 semanas

Ref. (35)

### **OU**

Raltitrexede: 3mg/m<sup>2</sup> IV D1

Mitomicina C: 7mg/m<sup>2</sup> IV D1

a cada 3 a 4 semanas

Ref. (28)

### **5-Fluorouracil + Leucovorin + Bevacizumabe**

5-Fluorouracil: 500 mg/m<sup>2</sup> IV semanalmente por 6 semanas

Leucovorin: 500 mg/m<sup>2</sup> IV semanalmente por 6 semanas,

Administrado antes do 5-Fluorouracil

Bevacizumabe: 5 mg/kg IV a cada 2 semanas

a cada 8 semanas

Ref. (18)

### **“de Gramont Regimen”**

5-Fluorouracil: 400 mg/m<sup>2</sup> IV seguido de 600 mg/m<sup>2</sup> IV por 22 horas D1 e D2

Leucovorin: 200 mg/m<sup>2</sup> IV D1 e 2 em infusão de 2 horas

a cada 2 semanas

Ref. (19)

### **FOLFOX4 + Bevacizumabe**

Oxaliplatina: 85 mg/m<sup>2</sup> IV D1

5-Fluorouracil: 400 mg/m<sup>2</sup> IV pulso, seguido por 600 mg/m<sup>2</sup> IV por infusão contínua D1 e D2

Leucovorin: 200 mg/m<sup>2</sup> IV D1 e 2 em infusão de 2 horas antes do 5-Fluorouracil

Bevacizumabe: 10 mg/kg IV a cada 2 semanas

a cada 2 semanas

Ref. (20)

### **Capecitabina + Oxaliplatina (XELOX) + Bevacizumabe**

Capecitabina: 850 mg/m<sup>2</sup> VO BID D1–14

Oxaliplatina: 130 mg/m<sup>2</sup> IV D1

Bevacizumabe: 7.5 mg/kg a cada 3 semanas

a cada 21 dias

Ref. (21)

### **FLOX**

Oxaliplatina: 85mg/m<sup>2</sup> IV em duas horas D1,15,29

Leucovorin: 500mg/m<sup>2</sup> IV D1, 8, 15, 22, 29, 36

5-Fluorouracil: 500mg/m<sup>2</sup> IV D1, 8, 15, 22, 29, 36

a cada 8 semanas por 3 ciclos

Ref. (27)

## **Capecitabina**

Capecitabina: 1.250 mg/m<sup>2</sup> VO BID D1–14

a cada 21 dias

Ref. (22)

## **Irinotecano (CPT11) (semanal)**

Irinotecano: 125 mg/m<sup>2</sup> IV em 90 minutos semanalmente

por 4 semanas.

a cada 6 semanas

Ref. (23)

Irinotecano: 125 mg/m<sup>2</sup> IV em 90 minutos semanalmente por 2 semanas. A cada 3 semanas.

Irinotecano: 175 mg/m<sup>2</sup> IV D1 e 10

a cada 3 semanas

Ref. (24)

Irinotecano: 350 mg/m<sup>2</sup> IV D1

a cada 3 semanas

Ref. (25)

## **Cetuximabe**

Cetuximabe: 400 mg/m<sup>2</sup> IV dose de ataque, seguido por 250 mg/m<sup>2</sup>

IV semanalmente

Ref. (26)

## **Cetuximabe + Irinotecano**

Irinotecano: 180mg/m<sup>2</sup> IV D1

Cetuximabe: 500mg/m<sup>2</sup> IV D1

a cada 15 dias

Ref. (36, 37)

## **b-Fol**

Oxaliplatina: 85mg/m<sup>2</sup> D1 e 15

Leucovorin: 20mg/m<sup>2</sup> D1, 8 e 15

5-Fluorouracil: 500mg/m<sup>2</sup> D1, 8 e 15

a cada 28 dias

Ref. (40)

## UFT

Leucovorin: 90 mg/dia VO D1 a D28

UFT: 100 mg/m<sup>2</sup> três vezes ao dia VO D1 a D28 a cada 35 dias

Ref. (41)

## FOLFIRI com bevacizumabe

Irinotecano: 180 mg/m<sup>2</sup> IV D1

Leucovorin: 200 mg/m<sup>2</sup> IV D1

5-Fluorouracil: 400 mg/m<sup>2</sup> IV pulso D1

5-Fluorouracil: 2400 mg/m<sup>2</sup> IV em infusão de 46 horas D1

Bevacizumabe: 5 mg/kg IV D1 a cada 14 dias

Ref. (42)

1. Sauer R, *et al.* Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004;351:1731–1740.
2. Minsky BD. Combined modality therapy of rectal cancer with oxaliplatin-based regimens. *Clin Colorectal Cancer* 2004; 4 Suppl 1:529–36.
3. O'Connell MJ, *et al.* Controlled trial of fluorouracil and low-dose leucovorin given por6 months as postoperative adjuvant therapy for colon cancer. *J Clin Oncol* 1997; 15: 246–250.
4. Wolmark N, *et al.* The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast eBowel Project Protocol C-03. *J Clin Oncol* 1993; 11: 1879–1887.
5. Benson AB, *et al.* NCCN practice guidelines for colorectal cancer. *Oncology* 2000;14:203–212.
6. de Gramont A, *et al.* Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized mosaic trial. *Proc Am Soc Clin Oncol* 2003;22:253 (abstract 1015).



7. Cassidy J, *et al.* Capecitabine (X) vs. bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial. *Proc Am Soc Clin Oncol* 2004;23:(abstract3509).
8. Saltz LB, *et al.* Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2000; 343: 905–914.
9. Hurwitz H, *et al.* Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350: 2335–2342.
10. Hwang JJ, *et al.* Capecitabine-based combination chemotherapy. *Am J Oncol Rev* 2003;2 (Suppl 5):15–25.
11. Douillard JY, *et al.* Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. *Lancet* 2000; 355: 1041–1047.
12. Andre T, *et al.* CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. *GERCOR. Eur J Cancer* 1999;35:1343–1347.
13. de Gramont A, *et al.* Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 2000;18:2938–2947.
14. Cunningham D, *et al.* Cetuximab monotherapy or cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004;351:337–345.
15. Scheithauer W, *et al.* Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 2003;21: 1307–1312.
16. Kerr D. Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. *Oncology* 2002;16 (Suppl 14):12–15.
17. Goldberg RM, *et al.* A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated

metastatic colorectal cancer. *J Clin Oncol* 2004;22:23–30.

18. Kabbinnavar F, *et al.* Results of a randomized phase II controlled trial of bevacizumab in combination with 5-fluorouracil leucovorin as first-line therapy in subjects with metastatic CRC. *Proc Am Soc Clin Oncol* 2004;23:Abstract 3516.
19. de Gramont A, *et al.* Randomized trial comparing monthly lowdose leucovorin efluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. *J Clin Oncol* 1997;15:808–815.
20. Mitchell EP, *et al.* High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at the 2005 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27–29, 2005 Hollywood, FL (abstract 169a).
21. Hochster HS, *et al.* Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized “TREE-2” trial. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27–29, 2005 Hollywood, FL (abstract 241).
22. Hoff P, *et al.* Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. *J Clin Oncol* 2001;15:2282–2292.
23. Pitot HC, *et al.* Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. *J Clin Oncol* 1997; 15: 2910–2919.
24. Ulrich-Pur H, *et al.* Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin- based first-line combination chemotherapy. *Ann Oncol* 2001; 12:1269–1272.

25. Rougier P, *et al.* Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. *J Clin Oncol* 1997;15:251–260.
26. Saltz LB, *et al.* Phase II trial of cetuximab in patients with refractory colorectal cancer that expressed the epidermal growth factor receptor. *J Clin Oncol* 2004;22:1201–1208.
27. Kuebler JP *et al.*: Oxaliplatin combined with weekly bolus of fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C07. *J Clin Oncol.* 2007; 25:2198-2204.
28. Murad AM, Aragao BC, Guimarães RC. Phase II Trial of the Use of Raltitrexed and Mitomycin-C in the Treatment of Advanced Colorectal Cancer after 5FU Failure: Final Results. *Proc Am Soc Clin Oncol*, 2001 (20) abst 2188.
29. D. J. Kerr, R. Gray, C. McConkey & J. Barnwell for the QUASAR Colorectal Cancer Study Group. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: Non-randomised comparison of weekly versus four-weekly schedules - less pain, same gain. *Ann Oncol* (2000) 11 (8): 947-955.
30. Sørbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, Øgreid D, Dahl O. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. *J Clin Oncol.* 2004 Jan 1; 22(1): 31-8.
31. Yamada Y, Ohtsu A, Boku N, Miyata Y, Shimada Y, Doi T, Muro K, Muto M, Hamaguchi T, Mera K, Yano T, Tanigawara Y, Shirao K. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer. *Jpn J Clin Oncol.* 2006 Apr; 36(4):218-23.
32. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D,

Georgoulas V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). *Br J Cancer*. 2006 Mar 27; 94(6):798-805.

33. Cortinovis D, Bajetta E, Di Bartolomeo M, Dognini G, Beretta E, Ferrario E, Ricotta R, Buzzoni R. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer. *Tumori*. 2004 Mar-Apr; 90(2):186-91.
34. Rosati G, Rossi A, Germano D, Reggiardo G, Manzione L. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. *Anticancer Res*. 2003 May-Jun; 23(3C):2981-5.
35. Michels J, Geldart T, Darby A, Craddock L, Iveson A, Richardson L, Iveson T. The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer - a phase II study. *Clin Oncol (R Coll Radiol)*. 2006 Aug;18(6):431-5.
36. P Martí n-Martorell1, S Rosello ´ 1, E Rodr í guez-Braun1, I Chirivella1, A Bosch1 and A Cervantes Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial *British Journal of Cancer* (2008) 99, 455–458.
37. Pfeiffer P, D. Nielsen, J. Bjerregaard, C. Qvortrup, M. Yilmaz & B. Jensen. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil *Annals of Oncology* 19: 1141–1145, 2008
38. Gray R, Barnwell J, McConkey C *et al*. Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. *Lancet*. 2007 Dec 15;370(9604):2020-9.

39. Hochster HS, Hart LL, *et al.* Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab as First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study. *J Clin Oncol*; 2008;26:3523-3529.
40. H. S. Hochster, A. Chachoua, J. Speyer, *et al.* Oxaliplatin with weekly bolus 5FU and low-dose leucovorin (bFOL) as first-line therapy of colorectal cancer; a phase II study.
41. Lembersky BC, *et al.* Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06. *J Clin Oncol* 2006;24:2059-64.
42. Kopetz SM, *et al.*, Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC), ASCO Annual Meeting Proceedings Part I, *J Clin Oncol*, 2006; 24, No 18S (Supplement): (Abstract 3579).